RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
DR REDDYS LABORATORIES LTD
Financials through fiscal 2026, year ended Mar 31, 2026
$13.08+0.01 (+0.08%)
Close on Oct 19, 2026
DR REDDYS LABORATORIES LTD revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Generics [Member] | ₹299.03B | ₹289.55B | ₹245.45B | ₹213.77B | ₹179.17B | ₹154.40B | ₹138.12B | ₹122.90B | ₹114.01B | ₹115.41B | 89.0% | +3.3% |
| Global Generic [Member] | ₹299.03B | ₹289.55B | ₹245.45B | ₹213.77B | ₹179.17B | ₹154.40B | ₹138.12B | ₹122.90B | ₹114.01B | ₹115.41B | 89.0% | +3.3% |
| Pharmaceutical Services and Active Ingredients [Member] | ₹34.77B | ₹33.85B | ₹29.80B | ₹29.07B | ₹30.74B | ₹31.98B | ₹25.75B | ₹24.14B | ₹21.99B | ₹21.28B | 10.4% | +2.7% |
| Pharmaceutical Services and Active Ingredient [Member] | ₹34.77B | ₹33.85B | ₹29.80B | ₹29.07B | ₹30.74B | ₹31.98B | ₹25.75B | ₹24.14B | ₹21.99B | ₹21.28B | 10.4% | +2.7% |
| Other segment [Member] | ₹2.13B | ₹2.14B | ₹3.91B | ₹3.04B | ₹4.48B | ₹3.34B | ₹2.78B | ₹2.06B | ₹1.78B | ₹1.76B | 0.6% | -0.5% |
| Proprietary Product [Member] | – | – | – | – | ₹1.61B | ₹523.00M | ₹7.95B | ₹4.75B | ₹4.25B | ₹2.36B | – | – |
| Proprietary Products [Member] | – | – | – | – | ₹1.61B | ₹523.00M | ₹7.95B | ₹4.75B | ₹4.25B | ₹2.36B | – | – |
| Others [Member] | – | – | – | – | ₹2.87B | ₹2.81B | ₹2.78B | ₹2.06B | ₹1.78B | ₹1.76B | – | – |
By product or service
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others [Member] | ₹118.72B | ₹94.40B | ₹72.83B | ₹67.47B | ₹68.96B | ₹60.95B | ₹49.58B | ₹40.45B | ₹36.09B | ₹34.52B | 35.3% | +25.8% |
| United States | ₹117.89B | ₹149.35B | ₹135.57B | ₹106.68B | ₹80.56B | – | – | – | – | – | 35.1% | -21.1% |
| India [Member] | ₹64.54B | ₹55.83B | ₹48.47B | ₹50.50B | ₹43.99B | ₹36.25B | ₹32.09B | ₹28.80B | ₹25.21B | ₹24.93B | 19.2% | +15.6% |
| Russia [Member] | ₹34.79B | ₹25.96B | ₹22.30B | ₹21.23B | ₹20.88B | ₹15.82B | ₹16.90B | ₹15.30B | ₹12.61B | ₹11.55B | 10.4% | +34.0% |
| United States [Member] | – | – | – | – | – | – | – | – | ₹68.12B | ₹69.82B | – | – |
| Russia [Member] | – | – | – | – | – | – | – | – | ₹12.61B | ₹11.55B | – | – |
| India [Member] | – | – | – | – | – | – | – | – | ₹25.21B | ₹24.93B | – | – |
| Others [Member] | – | – | – | – | – | – | – | – | ₹36.09B | ₹34.52B | – | – |
| Oncology [member] | – | – | – | – | ₹80.56B | ₹76.70B | ₹76.03B | ₹69.30B | ₹68.12B | ₹69.82B | – | – |
From the segment and revenue-disaggregation notes of Dr Reddys Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.